HRA000921
Title:
Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
Release date:
2021-06-10
Description:
Clinical resistance such as androgen receptor (AR) mutation, AR overexpression and AR splice variants restrict the second-generation antiandrogens benefit in castration-resistant prostate cancer (CRPC) patients. Several strategies have been involved in the development of novel antiandrogens to circumvent the occurring resistance. In this work, based on rational drug design, we discovered and identified a bifunctional small molecule Z15 as a potent AR antagonist and the AR selective degrader. Here, in this bioproject, we performed a RNA-seq to analysis the influence of Z15 on prostate cancer cells.
Data Accessibility:   
Open access
BioProject:
Study type:
Cell line related study
Dataset Download
MetaData:
Files:
Aspera Command Line:  Help   

 Note: HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client) or Asepra Command Line.

Individuals & samples
Files
Submitter:   Zhou Jinmign / zhou_jim@hotmail.com
Organization:   Zhejiang normal university
Submission date:   2021-06-07